Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...

We will be totally self-sufficient for the supply of medicines to American patients.” AstraZeneca CEO Pascal Soriot on the ...

Intervention/Treatment: The study tests AZD6234, an experimental drug administered through weekly subcutaneous injections. It is designed to work alongside existing GLP-1 RA therapy to improve ...

In an earnings call on July 29th, in which the company reported a 13% increase in half-year profits, he said about Britain ...

AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

Investors were clearly impressed by the company's second-quarter beats, especially the one on the bottom line.

After beating AstraZeneca’s Calquence in quarterly revenue for the first time at the end of 2024, BeOne Medicines’ Brukinsa ...

AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

AstraZeneca has admitted in court documents that its COVID-19 vaccine could cause a rare but deadly blood-clotting condition, potentially exposing the UK pharmaceutical giant to tens of millions ...